Phase III trial of tebipenem ends early after successfully having met primary endpoint: non-inferiority to IV imipenem-cilastatin for treating complicated urinary tract infections. If approved, it would become the first oral carbapenem available in the U.S.
#AMR

https://finance.yahoo.com/news/gsk-spero-halt-uti-antibiotic-114238462.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAABw82cHL1j8wTsYj8GGrXZi_JcNpXNnco4jr_LM_6GPMxZcbzKYpHOJN5_hD2oUpqU_ANVyDR4QJ3GDUA6oghn__eeDnXKkcuZWnZFJQ77bEH1DQnlsTJMxkBWhZqs8-p3PdebZsWVFeMWlE6iJh1OOESXKVHI7PAzwMy-R3nwWr